Related Experiment Video
Updated: Jun 23, 2026
06:16
Involving Individuals with Developmental Language Disorder and Their Parents/Carers in Research Priority Setting
Published on: June 6, 2020
Improving decision analyses: parent preferences (utility values) for pediatric health outcomes
Aaron E Carroll1, Stephen M Downs
1Children's Health Services Research, Indiana University School of Medicine, Indianapolis, IN, USA. aaecarro@iupui.edu
The Journal of Pediatrics
|April 28, 2009
Summary
This study calculated health utility values for pediatric conditions, providing crucial data for healthcare economic evaluations. Findings range from acute otitis media to severe mental retardation.
Area of Science:
- Pediatric Health Economics
- Health Utilities Measurement
Background:
- Health utilities are essential for economic evaluations in healthcare.
- Quantifying utilities for pediatric health states is critical for resource allocation.
Purpose of the Study:
- To gather and calculate utility values for diverse health states in children.
- To establish a comprehensive dataset for pediatric health economic analyses.
Main Methods:
- Recruited 4016 parents/guardians through the Pediatric Research Network (PResNet).
- Assessed utilities for 29 pediatric health states using time trade-off and standard gamble methods.
- Achieved an 88% recruitment rate across various public and clinical settings.
Main Results:
- Utility values spanned from 0.97 (acute otitis media, time trade-off) to 0.51 (severe mental retardation, time trade-off).
- Significant variation in utility values across different pediatric health conditions was observed.
Conclusions:
- The extensive dataset provides valuable utility assessments for pediatric health states.
- This data can significantly aid future economic evaluations of pediatric healthcare interventions.
Related Concept Videos
01:09Decision Making: P-value Method
The process of hypothesis testing based on the P-value method includes calculating the P- value using the sample data and interpreting it.
First, a specific claim about the population parameter is proposed. The claim is based on the research question and is stated in a simple form. Further, an opposing statement to the claim is also stated. These statements can act as null and alternative hypotheses: a null hypothesis would be a neutral statement while the alternative hypothesis can have a...
First, a specific claim about the population parameter is proposed. The claim is based on the research question and is stated in a simple form. Further, an opposing statement to the claim is also stated. These statements can act as null and alternative hypotheses: a null hypothesis would be a neutral statement while the alternative hypothesis can have a...
01:12Analysis of Population Pharmacokinetic Data
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...